

REMARKS

In the Office Action, the Examiner has required of the above-referenced application to one of the following inventions:

- Group I: Claims 1-42, drawn to a (1) a method for treating a neurodegenerative disease in a subject, (2) a method for treating epilepsy in a subject by delivering a vector encoding a glutamic acid decarboxylase (GAD), (3) a method for treating epilepsy in a subject by delivering an adeno-associated viral (AAV) vector encoding GAD, and (4) a method of altering expression of GAD in a region of the central nervous system (CNS) of a subject with epilepsy, classified in class 424, subclass 93.2 and class 514, 44;
- Group II: Claims 43-48, drawn to a vector comprising a nucleotide sequence encoding GAD classified in class 435, subclass 320.1.

Applicants hereby elect:

Group II: Claims 43-48.

Claims 1-42 are hereby withdrawn.

The Examiner has also required an election of species. Upon election of Group I or II, Applicants are required to elect one of the following covering different types of gene transfer vectors:

- A. Adenovirus vector;
- B. Herpes virus vector;
- C. Parvovirus vector;
- D. Lentivirus vector;
- E. Adeno-associated viral vector;

F. Liposome-mediated deliver vector.

Applicants hereby traverse this requirement. Applicants submit that claim 41 is generic and patentable regardless of the type of gene transfer vector used.


For the purposes of speeding prosecution, Applicants hereby elect:

Species E: Adeno-Associated Viral Vector

Applicants invite the Examiner to call the undersigned if there are any questions regarding the above election.

Dated: December 11, 2006

Respectfully submitted,

By 
George A. Nixis
Registration No.: 38,664
NUTTER MCCLENNEN & FISH LLP
World Trade Center West
155 Seaport Boulevard
Boston, Massachusetts 02210-2604
(617)439-2746
(617) 310-9746 (FAX)
Attorney for Applicants

1584982.1